Spratt DE, et al. Patterns of lymph node failure after dose-escalated radiotherapy: implications for extended pelvic lymph node coverage. Eur Urol. 2017;71(1):37–43.

Article  PubMed  Google Scholar 

Jackson WC, et al. Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. BJU Int. 2017;120(3):351–7.

Article  PubMed  Google Scholar 

Parker WP, et al. Identification of site-specific recurrence following primary radiation therapy for prostate cancer using C-11 choline positron emission tomography/computed tomography: a nomogram for predicting extrapelvic disease. Eur Urol. 2017;71(3):340–8.

Article  PubMed  Google Scholar 

Imber BS, et al. Failure patterns by PSMA PET for recurrent prostate cancer after prostatectomy and salvage radiation. Urology. 2022.

Raveenthiran S, et al. The use of (68)Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy. Prostate Cancer Prostatic Dis. 2019;22(3):385–90.

Article  CAS  PubMed  Google Scholar 

Raman S, et al. Patterns of prostate cancer recurrence after brachytherapy determined by prostate-specific membrane antigen-positron emission tomography and computed tomography imaging. Int J Radiat Oncol Biol Phys. 2022;112(5):1126–34.

Article  PubMed  Google Scholar 

Mena E, et al. Novel PET imaging methods for prostate cancer. World J Urol. 2021;39(3):687–99.

Article  PubMed  Google Scholar 

Galgano, SJ, et al. Defining oligometastatic disease in the new era of PSMA-PET imaging for primary staging of prostate cancer. Cancers (Basel). 2022;14(14).

Schwartz LH, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer. 2009;45(2):261–7.

Zarzour JG, et al. Lymph node imaging in initial staging of prostate cancer: an overview and update. World J Radiol. 2017;9(10):389–99.

Article  PubMed  PubMed Central  Google Scholar 

National Comprehensive Cancer Network. Prostate Cancer (Version 3.2022). April 22, 2022]; Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

Shipley WU, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417–28.

Article  PubMed  PubMed Central  Google Scholar 

Carrie C, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20(12):1740–9.

Article  CAS  PubMed  Google Scholar 

Onal C, et al. Oligometastatic bone disease in castration-sensitive prostate cancer patients treated with stereotactic body radiotherapy using 68Ga-PSMA PET/CT: TROD 09–004 study. Clin Nucl Med. 2021;46(6):465–70.

Article  PubMed  Google Scholar 

Siva S, et al. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74(4):455–62.

Article  PubMed  Google Scholar 

Créhange G, et al. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? Cancer Radiother. 2014;18(5–6):524–34.

Article  PubMed  Google Scholar 

Ponti E, et al. Salvage stereotactic body radiotherapy for patients with prostate cancer with isolated lymph node metastasis: a single-center experience. Clin Genitourin Cancer. 2015;13(4):e279–84.

Article  PubMed  Google Scholar 

Leroy T, et al. Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: preliminary results of the Oscar Lambret Center. Radiat Oncol. 2017;12(1):95.

Article  PubMed  PubMed Central  Google Scholar 

Lieng H, et al. Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiother Oncol. 2018;129(2):377–86.

Article  PubMed  Google Scholar 

Panje C, et al. Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. Radiat Oncol. 2019;14(1):177.

Article  PubMed  PubMed Central  Google Scholar 

Cozzi S, et al. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer: an investigation of 117 pelvic lymph nodes. Strahlenther Onkol. 2022;198(8):700–9.

Article  PubMed  Google Scholar 

Oehler C, et al. Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience. BMC Urol. 2019;19(1):84.

Article  PubMed  PubMed Central  Google Scholar 

Burkon P, et al. Stereotactic body radiotherapy for lymph node oligometastases: real-world evidence from 90 consecutive patients. Front Oncol. 2020;10: 616494.

Article  PubMed  Google Scholar 

Burkoň P, et al. Stereotactic body radiotherapy of lymph node oligometastases. Klin Onkol. 2020;33(2):114–22.

Article  PubMed  Google Scholar 

Franzese C, et al. Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. Br J Radiol. 2017;90(1079):20170422.

Article  PubMed  PubMed Central  Google Scholar 

• Ost P, et al. Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol (R Coll Radiol). 2016;28(9):e115–20. Most comprehensive report of pattern of recurrence following SBRT for oligorecurrent nodal prostate cancer.

Article  CAS  PubMed  Google Scholar 

Pinkawa M, et al. Radiotherapy in nodal oligorecurrent prostate cancer. Strahlenther Onkol. 2021;197(7):575–80.

Article  PubMed  PubMed Central  Google Scholar 

Afshar-Oromieh A, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44(8):1258–68.

Article  PubMed  PubMed Central  Google Scholar 

Hope TA, et al. Metaanalysis of (68)Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60(6):786–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tran S, et al. Oligorecurrent nodal prostate cancer: long-term results of an elective nodal irradiation approach. Am J Clin Oncol. 2018;41(10):960–2.

Article  PubMed  Google Scholar 

Zilli T, et al. Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus. Radiother Oncol. 2022;176:199–207.

Article  PubMed  Google Scholar 

• De Bruycker A, et al. PEACE V - Salvage treatment of oligorecurrent nodal prostate cancer metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer. 2020;20(1):406. First prospective evaluation evaluating metastasis-directed therapy (MDT) versus MDT in conjunction with whole pelvic radiotherapy in patients with oligometastatic recurrent prostate cancer detected on PSMA or choline PET.

Article  PubMed  PubMed Central  Google Scholar 

Verma J, et al. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys. 2014;88(2):357–62.

Article  PubMed  Google Scholar 

• Phillips R, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650–9. Treatment with SABR for oligometastatic prostate cancer improved outcomes and was enhanced by total consolidation of disease identified by PSMA-targeted positron emission tomography.

Article  PubMed  PubMed Central  Google Scholar 

Galgano SJ, et al. [(18)F]Fluciclovine-PET guided salvage lymph node dissection following radical prostatectomy. Urology. 2019;132:28–32.

Article  PubMed  Google Scholar 

McCloskey H, et al. Salvage pelvic lymph node dissection and current state of imaging for recurrent prostate cancer: does a standard exist? Curr Urol Rep. 2020;21(12):62.

Article  PubMed  Google Scholar 

Rogowski P, et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol. 2021;16(1):50.

Article  CAS  PubMed  PubMed Central  Google Scholar